Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Xeris Pharmaceuticals, Inc. United States

Xeris is a clinical-stage pharmaceutical company developing patient-friendly injectable drugs for various indications with an initial focus on diabetes. The current paradigm for many injectable drugs is to design formulations for delivery in water-based systems.  However, the presence of water is problematic because it actively degrades many molecules often preventing drug products from being packaged for use as a “ready-to-use” solution.  Xeris' patented and patent-pending XeriSol™ and XeriJect™ formulation technologies are transformative in their elimination of water. By replacing water with non-water, bio-compatible carriers already used in other FDA-approved drugs, Xeris solves a number of problems adding significant value to existing injectable drugs and to new drugs in development.  This technology is already being validated with the development of a non-aqueous glucagon formulation that has shown 24 months of room-temperature stability in solution and very positive safety and efficacy in a Phase 2 clinical study. While this product and other glucagon products are being developed and $20M has been raised to support this development, Xeris is seeking to spinoff its earlier stage non-glucagon assets and obtain funding (both equity and non-dilutive) to support these projects.  More specifically, these projects include the development of a non-aqueous, auto-injectable diazepam to replace the current diazepam rectal gel for treatment of epileptic seizures and a non-aqueous, intradermal auto-injectable epinephrine to replace the current, antiquated EpiPen.  

Website:
www.xerispharma.com
Year Founded
2005
Main Sector
Biotech Subsector
Indication
Biotech Phase of Development
Technology Overview
Non-aqueous (no water) injectable formulations
Supporting Metrics or Evidence
Stability data, preclinical data, clinical data, FDA interactions
Current Investors
Large family offices and high net worth investors from the pharma industry
IP Status
3 issued patents and 14 additional applications pending
Dr Yash Sabharwal
Dr Yash Sabharwal
LinkedIn logo Chief Operating Officer 

Yuzu Labs United States

Yuzu Labs, based in Silicon Valley, is a research startup that aims to make clinical, behavioral, and social research more accessible, easier, faster, and cheaper. We've recently launched a private beta of our initial product named StudyPages. Researchers can use this web application to quickly set up a dedicated webpage for their studies, share with target communities, and track signups. Please visit the site to learn more: https://studypages.com
Website:
http://yuzulabs.com
Year Founded
2014
Service Provider Type
Eron Villarreal
Eron Villarreal
LinkedIn logo Co-Founder 
BIO

Eron holds a computer science engineering degree and has broad experience in Silicon Valley startups spanning search (Inflection), mobile advertising (InMobi), electronic medical records (drchrono), and medical device development (Scanadu). At Yuzu Labs, Eron manages all things tech with a passion for quality, teamwork, and technology driven problem solving. After college, he lived in Japan for 5+ years, where he built a new life from scratch and became a hybrid of American and Japanese values.

I crave hard problems, believe that people united by a goal can change the world, work tirelessly for something I believe in, and am an optimist with no fear, despite the odds, as everything works out in the end.

Koen De Lombaert
Koen De Lombaert
LinkedIn logo Co-Founder 
BIO

Koen holds a MD (Catholic University Leuven, Belgium) and a MBA (Johns Hopkins University) and worked in lifesciences, bioinformatics, business development, marketing, and product management in academia, startups, and at Roche Pharmaceuticals. Koen enjoys technology and UX design and builds wireframes for new product ideas. His passion for science and entrepreneurshipmade him move stepwise from Belgium to the West and he calls Silicon Valley now his new home.

ZeroTo510 Medical Device Accelerator United States

The majority of medical devices get cleared for commercial deployment through the FDA’s 510(k) clearance process, which is the fastest and most economical route to market for a new medical device. ZeroTo510 has developed a unique program that enables entrepreneurs with ideas for innovative medical devices to take advantage of the fast path to market. ZeroTo510 is a first-of-its-kind cohort-based medical device accelerator. Hosted in Memphis, Tennessee, the program leverages key regional strengths in biomedical research and medical device manufacturing to create a unique program.

Website:
www.zeroto510.com
Year Founded
2012
Investor Type
Sector Interest
Medtech Subsector
Indication
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Allan Daisley
Allan Daisley
LinkedIn logo President 
BIO

Allan Daisley is the director of entrepreneurship and sustainability at Memphis Bioworks Foundation. In this role, he manages entrepreneurship and business incubation programs and helps to grow and support the entrepreneurship ecosystem in the Memphis area. He is the program director of the ZeroTo510 Medical Device Accelerator, an innovative, first-of-its-kind entrepreneurship program that helps entrepreneurs launch new medical device companies, navigate the startup process and deliver their products to market. ZeroTo510 uses a methodology that combines an intensive mentorship-driven, cohort-based program with a seed investment in each company.

 

Allan previously worked as an economic development consultant and managed a business incubator program focused on leveraging entrepreneurship and technology as key drivers of sustainable economic development. He also has spent time in senior strategy and marketing roles at IBM, as a consultant at Accenture, and as an entrepreneur in two start-up ventures. Allan has an MBA from Duke University and a Bachelor of Science in Computer Engineering from the Georgia Institute of Technology.